Invesco Ltd. Cue Biopharma, Inc. Transaction History

Invesco Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.77 - $3.09 $238 - $417	-135 Reduced 0.88%	15,207 $28,000
Q4 2023 Feb 12, 2024	SELL	$1.72 - $3.1 $3,962 - $7,142	-2,304 Reduced 13.06%	15,342 $40,000
Q2 2023 Aug 11, 2023	BUY	$3.11 - $4.91 $54,879 - $86,641	17,646 New	17,646 $64,000
Q2 2022 Aug 15, 2022	SELL	$2.49 - $5.92 $30,968 - $73,627	-12,437 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.41 - $12.28 $635 - $1,768	-144 Reduced 1.14%	12,437 $60,000
Q4 2021 Feb 14, 2022	SELL	$10.86 - $17.85 $1,976 - $3,248	-182 Reduced 1.43%	12,581 $142,000
Q3 2021 Nov 15, 2021	BUY	$10.06 - $15.3 $128,395 - $195,273	12,763 New	12,763 $186,000
Q2 2020 Aug 14, 2020	SELL	$12.7 - $30.73 $558,088 - $1.35 Million	-43,944 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$9.85 - $22.27 $148,242 - $335,163	-15,050 Reduced 25.51%	43,944 $623,000
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $416,497 - $1.03 Million	58,994 New	58,994 $937,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.